U-Ploid

Executive Summary

U-Ploid Biotechnologies is a UK-based biotech company developing a first-in-class therapeutic to improve egg quality in women aged mid-30s and above by targeting meiotic aneuploidy, a leading cause of infertility and miscarriage. The company's approach aims to seamlessly integrate into existing IVF procedures, addressing a significant unmet need as delayed childbearing increases globally. Founded in 2018 and based in Cambridge, U-Ploid leverages cutting-edge genetics and genomics to tackle age-related fertility decline. Its technology has the potential to enhance IVF success rates, reduce the need for multiple cycles, and lower the emotional and financial burden on patients. With no approved treatments specifically for egg quality improvement, U-Ploid's platform could become a standard adjunct in reproductive medicine, targeting a large and growing market. The company is privately held and at an early stage, with no disclosed funding or valuation, but its novel approach positions it as a notable player in reproductive therapeutics.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1 Clinical Trial50% success
• TBDStrategic Partnership with Major IVF Clinic Network40% success
• Q4 2026Series A Funding Round Completion60% success